American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 69-76 , January 2010

Nonrandomized Trial of Weight Loss With Orlistat, Nutrition Education, Diet, and Exercise in Obese Patients With CKD: 2-Year Follow-up

  • Helen L. MacLaughlin, BSc (Hons)

      Affiliations

    • Department of Nutrition and Dietetics, King's College Hospital, London, UK
    • Corresponding Author InformationAddress correspondence to Helen MacLaughlin, BSc (Hons), Department of Nutrition and Dietetics, King's College Hospital, Denmark Hill, London SE5 9RS, United Kingdom
    • ,
  • Sharlene A. Cook, BSc (Hons)

      Affiliations

    • Department of Physiotherapy, King's College Hospital, London, UK
    • ,
  • Deepa Kariyawasam, BSc (Hons)

      Affiliations

    • Department of Nutrition and Dietetics, King's College Hospital, London, UK
    • ,
  • Magnus Roseke

      Affiliations

    • Department of Renal Medicine, King's College Hospital, London, UK
    • ,
  • Marcelle van Niekerk, BSc, PGDip

      Affiliations

    • Department of Nutrition and Dietetics, King's College Hospital, London, UK
    • ,
  • Iain C. Macdougall, BSc (Hons), MD, FRCP

      Affiliations

    • Department of Renal Medicine, King's College Hospital, London, UK

Received 10 February 2009 ,Accepted 4 September 2009.

References 

  1. Hallan S, de Mutsert R, Carlsen S, Dekker FW, Aasarod K, Holmen J. Obesity, smoking, and physical inactivity as risk factors for CKD: are men more vulnerable?. Am J Kidney Dis. 2006;47:396–405
  2. Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis. 2005;46:871–880
  3. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol. 2006;17(suppl 2):S81–S85
  4. Hsu C, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–28
  5. Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol. 2006;17:1453–1459
  6. Praga M. Obesity—a neglected culprit in renal disease. Nephrol Dial Transplant. 2002;17:1157–1159
  7. de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillaga HL PREVEND Study Group. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord. 2002;26(suppl 4):S21–S24
  8. Johnson DW, Isbel NM, Brown AM, et al. The effect of obesity on renal transplant outcomes. Transplantation. 2002;74:675–681
  9. Singh D, Lawen J, Alkhudair W. Does pretransplant obesity affect the outcome in kidney transplant recipients?. Transplant Proc. 2005;37:717–720
  10. Espejo B, Torres A, Valentin M, et al. Obesity favors surgical and infectious complications after renal transplantation. Transplant Proc. 2003;35:1762–1763
  11. Parikh CR, Klem P, Wong C, Yalavarthy R, Chan L. Obesity as an independent predictor of posttransplant diabetes mellitus. Transplant Proc. 2003;35:2922–2926
  12. Miller RM, Rollnick S. Motivational Interviewing: Preparing People for Change. 2nd ed.. London, UK: Guildford Press; 2002;
  13. Cooper Z, Fairburn CG, Hawker DM. Cognitive-Behavioural Treatment of Obesity. New York, NY: Guildford Press; 2003;
  14. EDTNA/ERCA. European Guidelines for the Nutritional Care of Adult Renal Patients. Eur Dial Transplant Nurses Assoc/Eur Ren Care Assoc J. 2003;29:S1–S23http://www.library.nhs.uk/kidney/ViewResource.aspx?resID=155466. Accessed June 13, 2007
  15. Renal Association. Clinical Practice Guidelines. 4th ed http://www.renal.org/guidelines/index.htmlAccessed June 29, 2007
  16. Borg G. Borg's Perceived Exertion and Pain Scales. Champaign, IL: Human Kinetics; 1998;
  17. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21(suppl 3):S12–S23
  18. Qureshi AR, Alvestrand A, Danielsson A, et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int. 1998;53:773–782
  19. Suliman ME, Qureshi AR, Stenvinkel P, et al. Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. Am J Clin Nutr. 2005;82:342–349
  20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation (Modification of Diet in Renal Disease Study Group). Ann Intern Med. 1999;130:461–470
  21. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol. 2000;11:0828A
  22. Cook S, MacLaughlin HL, Macdougall IC. A structured weight management programme can achieve improved functional ability and significant weight loss in obese patients with chronic kidney disease. Nephrol Dial Transplant. 2008;23:263–268
  23. Jesty K, Walker R, Hazeldine J, et al. A multidisciplinary weight loss programme for patients with chronic kidney disease stage 5 [abstract]. Surrey, UK: British Renal Society; 2007;British Renal Society Annual Conference Proceedings:112
  24. Sjöstrom L, Rissanen A, Andersen T, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167–172
  25. Davidson MH, Hauptman J, DiGiorlamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235–242
  26. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care. 2004;27:155–161
  27. Lingarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish multimorbidity study. J Intern Med. 2000;248:245–254
  28. Broom I, Wilding J, Stott P, Myers N. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. Int J Clin Prac. 2002;56:494–499
  29. Hollander P, Elbein S, Hirsch I, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes (A one year randomised double blind study). Diabetes Care. 1998;21:1288–1294
  30. Kelley D, Bray G, Pi-Sunyer F, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin treated type 2 diabetes: a 1-year randomised controlled trial. Diabetes Care. 2002;25:1033–1041

 Originally published online as doi:10.1053/j.ajkd.2009.09.011 on November 18, 2009.

PII: S0272-6386(09)01260-8

doi: 10.1053/j.ajkd.2009.09.011

American Journal of Kidney Diseases
Volume 55, Issue 1 , Pages 69-76 , January 2010

Article Tools

* Image Usage & Resolution